# Milad Nazarzadeh, DPhil (Oxon)

**Senior Research Fellow in Cardiovascular & Genetic Epidemiology**  
University of Oxford | Deep Medicine, Nuffield Department of Women's and Reproductive Health

[![ORCID](https://img.shields.io/badge/ORCID-0000--0002--0576--8874-green.svg)](https://orcid.org/0000-0002-0576-8874)
[![Website](https://img.shields.io/badge/Website-Oxford-blue)](https://www.wrh.ox.ac.uk/team/milad-nazarzadeh)
[![Email](https://img.shields.io/badge/Email-milad.nazarzadeh%40wrh.ox.ac.uk-red)](mailto:milad.nazarzadeh@wrh.ox.ac.uk)

---

## üìä Professional Summary

Senior Scientist specialising in **cardiovascular medicine**, **biostatistics**, and **epidemiology**, with expertise in big data analysis, electronic health records, genetic data analysis, machine learning, deep learning, and causal inference. Leading investigator in the **Blood Pressure Lowering Treatment Trialists' Collaboration** and core member of the **Deep Medicine** research group at Oxford.

**Research Impact:**
- **83 peer-reviewed publications** | **h-index: 30** | **16,742+ citations**
- Lead/senior author on landmark papers in *The Lancet*, *JAMA Cardiology*, *European Heart Journal*
- Expert in individual participant-level data meta-analyses with over 300,000 randomised participants
- Pioneering applications of AI/ML to cardiovascular risk prediction and clinical decision support

---

## üéì Education

**Doctor of Philosophy (DPhil) | University of Oxford** *(2019-2022)*  
- Focus: Computational Epidemiology, Causal Inference, Cardiovascular Disease Modelling, Big Data Analysis
- Funded by: British Heart Foundation

**Master of Science (MSc) in Epidemiology and Biostatistics**  
*Shahid Beheshti University of Medical Sciences, Tehran* *(2010-2013)*

**Bachelor of Science (BSc) in Public Health**  
*Zanjan University of Medical Sciences* *(2008-2010)*

---

## üíº Professional Experience

**Senior Research Fellow in Cardiovascular & Genetic Epidemiology** *(2024 ‚Äì Present)*  
*Deep Medicine Group, University of Oxford*
- Leading clinical and epidemiology research teams in cardiovascular disease prevention
- Designing and validating risk stratification models using multi-modal biomedical data
- Supervising four PhD students and postdoctoral researchers
- Managing large-scale collaborative international research projects

**Postdoctoral Research Fellow** *(2023 ‚Äì 2024)*  
*Nuffield Department of Women's and Reproductive Health, University of Oxford*

**Genetic Epidemiologist** *(2018 ‚Äì 2019)*  
*Deep Medicine, The George Institute for Global Health, University of Oxford*

**Faculty Member in Epidemiology & Biostatistics** *(2015 ‚Äì 2018)*  
*Sabzevar University of Medical Sciences, Iran*

---

## üî¨ Selected Publications

### Blood Pressure & Cardiovascular Prevention

#### **1. Pharmacological blood pressure lowering for primary and secondary prevention across different levels of blood pressure**
*Lancet. 2021 May 1;397(10285):1625-1636* | [DOI: 10.1016/S0140-6736(21)00590-0](https://doi.org/10.1016/S0140-6736(21)00590-0)

**High-level summaries of importance:**
- **Paradigm shift in hypertension guidelines**: Demonstrated that blood pressure lowering reduces cardiovascular risk by ~10% per 5 mm Hg reduction across all baseline BP levels, including normal ranges (<130 mm Hg), challenging traditional treatment thresholds.
- **Impact on global health policy**: With 1.3 billion people affected by hypertension worldwide, findings support treating based on cardiovascular risk rather than arbitrary BP thresholds, potentially preventing millions of cardiovascular events globally.

---

#### **2. Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy**
*Lancet. 2021 Sep 18;398(10305):1053-1064* | [DOI: 10.1016/S0140-6736(21)01921-8](https://doi.org/10.1016/S0140-6736(21)01921-8)

**High-level summaries of importance:**
- **Evidence for treatment in elderly populations**: Proved pharmacological BP reduction remains effective up to age 85 years, with consistent relative risk reductions across all age groups, supporting removal of age-related treatment thresholds from clinical guidelines.
- **Precision medicine approach**: Showed that while relative risk reductions are consistent, absolute benefits increase with age due to higher baseline risk, enabling better risk-stratified treatment decisions in clinical practice.

---

#### **3. Blood pressure lowering and risk of new-onset type 2 diabetes**
*Lancet. 2021 Nov 13;398(10313):1803-1810* | [DOI: 10.1016/S0140-6736(21)01920-6](https://doi.org/10.1016/S0140-6736(21)01920-6)

**High-level summaries of importance:**
- **Dual cardiovascular-metabolic benefit**: Revealed that BP lowering reduces new-onset diabetes risk by 11% per 5 mm Hg reduction, with ACE inhibitors and ARBs showing the strongest protective effects, adding an important metabolic dimension to cardiovascular treatment.
- **Drug class-specific effects**: Identified that different antihypertensive classes have qualitatively different impacts on diabetes risk (protective vs harmful), providing critical evidence for personalised medication selection in at-risk populations.

---

#### **4. Blood pressure-lowering treatment in people with and without type 2 diabetes**
*Lancet Diabetes Endocrinol. 2022 Sep;10(9):645-654* | [DOI: 10.1016/S2213-8587(22)00172-3](https://doi.org/10.1016/S2213-8587(22)00172-3)

**High-level summaries of importance:**
- **Unified treatment approach for diabetes**: Demonstrated that BP-lowering treatment effects are similar in people with and without type 2 diabetes, refuting the need for differential BP thresholds based on diabetes status and simplifying clinical guidelines.
- **Evidence for 130 million people globally**: Provided robust evidence that people with diabetes benefit equally from BP reduction across all baseline levels, informing treatment for one of the world's largest chronic disease populations.

---

#### **5. Blood Pressure Lowering and Risk of Cancer: Individual Participant-Level Data Meta-Analysis**
*JACC CardioOncol. 2025 Aug;7(5):609-623* | [DOI: 10.1016/j.jaccao.2025.03.005](https://doi.org/10.1016/j.jaccao.2025.03.005)

**High-level summaries of importance:**
- **Safety reassurance for lifelong therapy**: Analysed 314,016 participants and found no evidence that long-term BP-lowering medication increases cancer risk, providing crucial safety data to address major patient and clinician concerns about chronic antihypertensive use.
- **Methodological innovation**: Combined randomised trial data with Mendelian randomisation to assess both short-term and lifetime effects, offering the most comprehensive evaluation of BP treatment and cancer risk to date.

---

#### **6. Sex-Specific Effects of Blood Pressure Lowering Pharmacotherapy**
*Hypertension. 2023 Nov;80(11):2293-2302* | [DOI: 10.1161/HYPERTENSIONAHA.123.21496](https://doi.org/10.1161/HYPERTENSIONAHA.123.21496)

**High-level summaries of importance:**
- **Equality in treatment benefit**: Analysed 358,636 participants (42% women) and found equivalent BP-lowering effects and cardiovascular risk reduction in women and men across all BP levels and drug classes, refuting concerns about sex-based differences.
- **Evidence for equitable guidelines**: Eliminated justification for sex-specific treatment thresholds or drug selection, supporting unified evidence-based guidelines and addressing historical underrepresentation of women in cardiovascular trials.

---

### Valvular Heart Disease & Causal Inference

#### **7. Plasma lipids and risk of aortic valve stenosis: a Mendelian randomization study**
*Eur Heart J. 2020 Oct 21;41(40):3913-3920* | [DOI: 10.1093/eurheartj/ehaa070](https://doi.org/10.1093/eurheartj/ehaa070)

**High-level summaries of importance:**
- **First causal evidence for preventable valve disease**: Used genetic instruments to demonstrate that lifelong exposure to elevated LDL-cholesterol increases aortic stenosis risk by 52% per 0.98 mmol/L, suggesting statins may prevent this previously 'untreatable degenerative' condition.
- **Paradigm shift in valvular heart disease**: Challenged the long-held view that aortic stenosis is purely degenerative, opening new avenues for pharmacological prevention in a condition affecting millions and currently only treatable by surgery.

---

#### **8. Systolic Blood Pressure and Risk of Valvular Heart Disease: A Mendelian Randomization Study**
*JAMA Cardiol. 2019 Aug 1;4(8):788-795* | [DOI: 10.1001/jamacardio.2019.2202](https://doi.org/10.1001/jamacardio.2019.2202)

**High-level summaries of importance:**
- **Novel modifiable risk factor identified**: First genetic study to demonstrate causal association between elevated BP and valvular heart disease (aortic stenosis, regurgitation, mitral regurgitation), revealing BP as a potentially modifiable risk factor.
- **Public health implications**: With ~100 million people affected by valvular disease globally, findings suggest BP control could represent a cost-effective prevention strategy for conditions currently requiring expensive surgical interventions.

---

#### **9. Genetic susceptibility, elevated blood pressure, and risk of atrial fibrillation**
*Genome Med. 2021 Mar 4;13(1):38* | [DOI: 10.1186/s13073-021-00849-3](https://doi.org/10.1186/s13073-021-00849-3)

**High-level summaries of importance:**
- **Gene-environment interaction uncovered**: Demonstrated that BP effects on atrial fibrillation vary by genetic susceptibility, with strongest effects in genetically high-risk individuals, pioneering precision prevention strategies.
- **Genomic risk stratification**: Showed potential for combining genetic risk scores with BP management to optimally prevent AF, the most common arrhythmia affecting 33 million people globally.

---

#### **10. Blood Pressure and Risk of Venous Thromboembolism**
*Cardiovasc Res. 2023 May 2;119(3):835-842* | [DOI: 10.1093/cvr/cvac135](https://doi.org/10.1093/cvr/cvac135)

**High-level summaries of importance:**
- **Unexpected protective effect discovered**: Revealed inverse association between BP and VTE risk (7% reduction per 20 mm Hg), confirmed through Mendelian randomization, identifying a novel cardio-haematological interaction.
- **Nuanced risk-benefit assessment**: Highlighted that in patients with VTE predisposing factors, aggressive BP lowering should be approached cautiously, demonstrating complexity of personalising treatment in multi-morbid populations.

---

### AI/Machine Learning & Digital Health

#### **11. Refined Selection for Preventive CVD Treatment with a Transformer-Based Risk Model**
*Lancet Digit Health. 2025 Jun;7(6):100873* | [DOI: 10.1016/j.landig.2025.03.005](https://doi.org/10.1016/j.landig.2025.03.005)

**High-level summaries of importance:**
- **AI-powered precision medicine**: Developed TRisk, a transformer-based deep learning model that outperforms established risk scores (C-index 0.910 vs 0.797), enabling more accurate identification of individuals who would benefit from preventive treatment.
- **Reducing treatment burden**: Could reduce the number of people requiring treatment by 20-35% while preventing at least as many events, addressing the challenge of overtreatment in cardiovascular prevention and improving cost-effectiveness.

---

#### **12. Deep Learning for Electronic Health Records: A Comparative Review**
*J Biomed Inform. 2020 Jan;101:103337* | [DOI: 10.1016/j.jbi.2019.103337](https://doi.org/10.1016/j.jbi.2019.103337)

**High-level summaries of importance:**
- **Comprehensive AI methods evaluation**: Provided first systematic comparison of deep learning architectures for EHR data, establishing benchmarks and best practices that have guided subsequent AI development in healthcare.
- **Foundation for clinical AI implementation**: Created methodological framework used by researchers and health systems worldwide to develop and validate AI tools for clinical decision support, influencing deployment of AI in real-world healthcare settings.

---

#### **13. Predicting the Risk of Emergency Admission with Machine Learning**
*PLoS Med. 2018 Nov;15(11):e1002695* | [DOI: 10.1371/journal.pmed.1002695](https://doi.org/10.1371/journal.pmed.1002695)

**High-level summaries of importance:**
- **Health system efficiency breakthrough**: Developed machine learning models achieving 84.8% accuracy in predicting emergency admissions up to 2 years in advance, enabling proactive resource allocation and preventive interventions.
- **Cost reduction potential**: Emergency admissions account for 70% of hospital bed days and billions in healthcare costs; accurate prediction enables targeted prevention strategies that could substantially reduce this burden.

---

### Drug Safety & Treatment Effects

#### **14. Antihypertensive treatment and risk of cancer**
*Lancet Oncol. 2021 Apr;22(4):558-570* | [DOI: 10.1016/S1470-2045(21)00033-4](https://doi.org/10.1016/S1470-2045(21)00033-4)

**High-level summaries of importance:**
- **Resolving long-standing safety controversy**: Comprehensive analysis of 260,447 participants found no association between any major antihypertensive drug class and cancer risk, addressing decades of conflicting evidence and patient concerns.
- **Clinical confidence for prescribers**: Provided definitive reassurance for the billions of people worldwide on long-term BP medication, removing a major barrier to treatment adherence and guideline implementation.

---

### Global Health

#### **15. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019**
*J Am Coll Cardiol. 2020 Dec 22;76(25):2982-3021* | [DOI: 10.1016/j.jacc.2020.11.010](https://doi.org/10.1016/j.jacc.2020.11.010)

**High-level summaries of importance:**
- **Comprehensive global disease surveillance**: Quantified CVD burden across 204 countries (18.6 million deaths, 523 million cases), providing the most comprehensive assessment of cardiovascular disease patterns essential for global health policy and resource allocation.
- **Alarming trend reversal identified**: Documented concerning increases in age-standardised CVD rates in some high-income countries and persistent rises in low-income countries, highlighting urgent need for renewed prevention efforts worldwide.

---

## üèÜ Awards & Honors

- **Award for Excellence**, NDWRH Department, University of Oxford (2024)
- **Immediate Postdoctoral Research Fellowship**, British Heart Foundation (2022)
- **PhD Scholarship**, British Heart Foundation (2019)
- **Young Researcher Grant**, 29th European Meeting on Hypertension (2019)
- **National Elite Foundation Award**, Tehran (2015)

---

## üí° Key Research Contributions

### Blood Pressure Lowering Treatment Trialists' Collaboration
- **Lead Statistician** for the world's largest collaboration on blood pressure treatment
- Oversee analysis of individual participant data from >50 randomised trials
- Over **350,000 participants** | **15+ years** of follow-up data
- Published landmark papers reshaping international hypertension guidelines

### Methodological Innovations
- Pioneering use of **individual participant-level data meta-analysis** in cardiovascular medicine
- Advanced **Mendelian randomization** methods for causal inference
- Development of **transformer-based deep learning** models for risk prediction
- Integration of **multi-modal health data** (genetics, EHR, biomarkers) for precision medicine

### Clinical Impact
- Research directly influenced **2024 European Society of Hypertension guidelines**
- Evidence cited in **NICE**, **AHA/ACC**, and **WHO** clinical recommendations
- Findings incorporated into **cardiovascular risk calculators** used worldwide
- Supported policy changes affecting **>1 billion people** with hypertension globally

---

## ü§ù Collaboration & Industry Engagement

**Lead Statistician & Research Methodologist**  
*Roche & University of Oxford Joint Research Project* (2024 ‚Äì Present)

**Speaker/Lecturer**  
*AstraZeneca Training Workshop on Hypertension* (2023)

**Statistical & Methodological Advisor**  
*Heart BMJ Journal, BMJ Publishing Group* (2024 ‚Äì Present)

**Part-Time Data Scientist**  
*Albus Health, Oxford* (2022)

**Methodological Consultant**  
*Nemysis Clinical Trial* (2023)

---

## üåê Professional Memberships

- **European Society of Cardiology** (Professional Member, 2019 ‚Äì Present)
- **ESC Council on Cardiovascular Genomics** (Member, 2019 ‚Äì Present)
- **Honorary Research Fellow**, MRC Integrative Epidemiology Unit, University of Bristol (2023 ‚Äì Present)

---

## üìö Leadership & Mentorship

- **Lead** of Clinical/Epidemiology Group, Deep Medicine, University of Oxford
- **Lead** of Core Statistical Analysis Team, Blood Pressure Lowering Treatment Trialists' Collaboration
- **Supervisor** of four PhD students and postdoctoral researchers
- **Reviewer** for *Lancet*, *JAMA*, *European Heart Journal*, *Circulation*, *BMJ*

---

## üõ†Ô∏è Technical Skills

**Statistical Software**: R, Python, Stata, SPSS  
**Machine Learning**: TensorFlow, PyTorch, scikit-learn  
**Cloud Analytics**: Google Cloud Platform, AWS  
**Data Analysis**: Causal inference, Survival analysis, Meta-analysis, Network meta-analysis  
**Genomics**: GWAS analysis, Mendelian randomization, Polygenic risk scores

---

## üì¨ Contact

**Email**: milad.nazarzadeh@wrh.ox.ac.uk  
**Office**: Deep Medicine, Osney One Building, Osney Mead, University of Oxford, OX2 0EW, United Kingdom  
**Mobile**: +44 7774 265749  
**ORCID**: [0000-0002-0576-8874](https://orcid.org/0000-0002-0576-8874)  
**Website**: [https://www.wrh.ox.ac.uk/team/milad-nazarzadeh](https://www.wrh.ox.ac.uk/team/milad-nazarzadeh)

---

*Last updated: November 2025*